← Evidence map

ArticleCancer medicine2026

Real-World Outcomes of Polatuzumab Vedotin Plus R-CHP Versus R-CHOP-Based Regimens in Japanese Patients With Untreated Diffuse Large B-Cell Lymphoma.

Masaaki Hotta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

2 papers cite it

2026

this papercites it

Real-World Outcomes of Polatuzumab Vedotin Plus R-CHP Versus R-CHOP-Based Regimens in Japanese Patients With Untreated Diffuse Large B-Cell Lymphoma. | OpenQuestion